These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 27232217)

  • 1. Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved.
    Hanseeuw B; Dricot L; Lhommel R; Quenon L; Ivanoiu A
    J Alzheimers Dis; 2016 May; 53(2):651-60. PubMed ID: 27232217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased hippocampal metabolism in high-amyloid mild cognitive impairment.
    Hanseeuw BJ; Schultz AP; Betensky RA; Sperling RA; Johnson KA
    Alzheimers Dement; 2016 Dec; 12(12):1288-1296. PubMed ID: 27421609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
    Tosun D; Schuff N; Jagust W; Weiner MW;
    Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
    Altomare D; Ferrari C; Caroli A; Galluzzi S; Prestia A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo ILH; Grimmer T; Redolfi A; Nordberg A; Scheltens P; Drzezga A; Frisoni GB;
    J Neurol; 2019 Oct; 266(10):2535-2545. PubMed ID: 31267207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatially Distributed Amyloid-β Reduces Glucose Metabolism in Mild Cognitive Impairment.
    Carbonell F; Zijdenbos AP; Bedell BJ;
    J Alzheimers Dis; 2020; 73(2):543-557. PubMed ID: 31796668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
    Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
    Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia.
    Mosconi L; Andrews RD; Matthews DC
    J Alzheimers Dis; 2013; 35(3):509-24. PubMed ID: 23478305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease.
    Khan W; Giampietro V; Banaschewski T; Barker GJ; Bokde AL; Büchel C; Conrod P; Flor H; Frouin V; Garavan H; Gowland P; Heinz A; Ittermann B; Lemaître H; Nees F; Paus T; Pausova Z; Rietschel M; Smolka MN; Ströhle A; Gallinat J; Vellas B; Soininen H; Kloszewska I; Tsolaki M; Mecocci P; Spenger C; Villemagne VL; Masters CL; Muehlboeck JS; Bäckman L; Fratiglioni L; Kalpouzos G; Wahlund LO; Schumann G; Lovestone S; Williams SC; Westman E; Simmons A; ; ;
    J Alzheimers Dis; 2017; 56(3):1159-1174. PubMed ID: 28157104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
    Chung JK; Plitman E; Nakajima S; Caravaggio F; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Shinagawa S; Patel R; Chakravarty MM; Graff-Guerrero A;
    J Alzheimers Dis; 2017; 58(3):747-762. PubMed ID: 28505977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
    Ye BS; Seo SW; Kim CH; Jeon S; Kim GH; Noh Y; Cho H; Yoon CW; Kim HJ; Jang EY; Lee J; Kim JH; Chin J; Lee JM; Kim JH; Seong JK; Kim CH; Choe YS; Lee KH; Na DL
    Neurobiol Aging; 2014 Feb; 35(2):291-300. PubMed ID: 24080178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
    Botha H; Mantyh WG; Murray ME; Knopman DS; Przybelski SA; Wiste HJ; Graff-Radford J; Josephs KA; Schwarz CG; Kremers WK; Boeve BF; Petersen RC; Machulda MM; Parisi JE; Dickson DW; Lowe V; Jack CR; Jones DT
    Brain; 2018 Apr; 141(4):1201-1217. PubMed ID: 29538658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.